Exhibit 107.1
Calculation of Filing Fee Table
Form S-8
(Form Type)
Elite Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security
Type | | Security Class Title | | Fee
Calculation
Rule | | | Amount
Registered(1) | | | Proposed
Maximum
Offering
Price Per
Unit | | | Maximum
Aggregate Offering
Price | | | Fee Rate | | | Amount of
Registration
Fee | |
| Equity | | Common Stock, $0.001 par value per share, reserved for issuance pursuant to the 2024 Elite Pharmaceuticals, Inc. Equity Incentive Plan | | | 457 | (h) | | | 80,000,000 | | | $ | 0.150 | (2) | | $ | 12,000,000 | | | | 0.0001476 | | | $ | 1,771.20 | |
| | | Total Offering Amounts | | | | | | | 80,000,000 | | | | | | | $ | 12,000,000 | | | | | | | $ | 1,771.20 | |
| | | Total Fee Offsets | | | | | | | | | | | | | | | | | | | | | | | — | |
| | | Net Fee Due | | | | | | | | | | | | | | | | | | | | | | $ | 1,771.20 | |
| (1) | Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under either the 2024 Elite Pharmaceuticals, Inc. Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock. |
| (2) | Estimated in accordance with Rule 457(h)(1) under the Securities Act solely for purposes of calculating the registration fee, based on the average of the high and low sales prices for the common stock as reported on the OTC Market on March 26, 2024. |
